Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
  • TickerMRNA
  • ISINUS60770K1079
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Des avancées scientifiques pour avoir une longueur d’avance

>La science reste le nerf de la guerre - Moderna organisait hier son 4eme CMD tourné sur la Science. Résumé ici en quelques lignes les ambitions, opportunités mais aussi défis d’une plateforme technologique qui est qu’au début de son histoire n’est pas chose aisée. En 2021, Moderna ambitionne de réaliser plus de 19 Md$ de ventes grâce à son vaccin COVID-19 ce qui en fera un des acteurs les plus importants du marché du vaccin global. Ces ventes accompagnées d’une ...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Scientific advances to provide a lead

>The science remains key - Yesterday Moderna held its fourth ‘Science Day’. Summarising here in several lines the ambitions, opportunities but also the challenges of a technology platform that is just at the beginning of its history is no mean feat. In 2021, Moderna aims to achieve sales of more than $ 19bn thanks to its COVID-19 vaccine making it one of the most significant players on the global vaccine market. These sales combined with strong profitability shou...

Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/05/2021

We held our twenty-sixth ABN AMRO - ODDO BHF Benelux Forum this week. The second year in a row on a fully virtual platform. With 32 Benelux issuers, 201 institutional investors and more than 500 meetings this is the largest dedicated Benelux conference held each year. - ...

Olfa Taamallah ...
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/07/2021 /

RATIONAL is the world market leader in cooking appliances for professional kitchens. The group boasts an excellent track record in terms of top line growth (2010-19 sales CAGR: 10.3%), profitability (average EBIT margin: 27.7%) FCF generation (€ 103m on average). Lack of visibility and catalysts in the short term and a demanding valuation (2023e P/E of 54x vs historic P/E of 44x) prompted us to initiate coverage of the stock with an Underperform rating and a target price of € 585. - ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need ...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Des avancées scientifiques pour avoir une longueur d’avance

>La science reste le nerf de la guerre - Moderna organisait hier son 4eme CMD tourné sur la Science. Résumé ici en quelques lignes les ambitions, opportunités mais aussi défis d’une plateforme technologique qui est qu’au début de son histoire n’est pas chose aisée. En 2021, Moderna ambitionne de réaliser plus de 19 Md$ de ventes grâce à son vaccin COVID-19 ce qui en fera un des acteurs les plus importants du marché du vaccin global. Ces ventes accompagnées d’une ...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Scientific advances to provide a lead

>The science remains key - Yesterday Moderna held its fourth ‘Science Day’. Summarising here in several lines the ambitions, opportunities but also the challenges of a technology platform that is just at the beginning of its history is no mean feat. In 2021, Moderna aims to achieve sales of more than $ 19bn thanks to its COVID-19 vaccine making it one of the most significant players on the global vaccine market. These sales combined with strong profitability shou...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : 2021 guidance adjusted upwards – Growth prospects reiterated

>First quarterly profit for the group - Moderna yesterday evening reported its Q1 2021 results, historically its first quarter in the black. While the top line came in a shade below expectations at $ 1.93bn (vs consensus at $ 2bn), profitability was higher than expected with net profit of $ 1.2bn (vs $ 832m expected). This outperformance was partly due to lower-than- expected COGS (11% of sales vs 23% expected) as a result of the recognition of part of the storage cos...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Guidance 21 ajustée à la hausse relevée – Des perspectives de croissance réitérées

>Premier trimestre bénéficiaire du groupe - Moderna a publié hier ses résultats du T1 2021, historiquement son premier trimestre bénéficiaire. Tandis que la topline ressort légèrement en dessous des attentes à 1.93 Md$ (vs Cs à 2 Md$), la profitabilité est, quant à elle, plus élevée qu’attendu avec un résultat net de 1.2 Md$ (vs 832 M$ attendus). Une surperformance due en partie à des COGS moins élevés qu’anticipé (11% des ventes vs 23% attendu) sous l’effet de la com...

Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/05/2021

We held our twenty-sixth ABN AMRO - ODDO BHF Benelux Forum this week. The second year in a row on a fully virtual platform. With 32 Benelux issuers, 201 institutional investors and more than 500 meetings this is the largest dedicated Benelux conference held each year. - ...

Olfa Taamallah ...
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/07/2021 /

RATIONAL is the world market leader in cooking appliances for professional kitchens. The group boasts an excellent track record in terms of top line growth (2010-19 sales CAGR: 10.3%), profitability (average EBIT margin: 27.7%) FCF generation (€ 103m on average). Lack of visibility and catalysts in the short term and a demanding valuation (2023e P/E of 54x vs historic P/E of 44x) prompted us to initiate coverage of the stock with an Underperform rating and a target price of € 585. - ...

Olfa Taamallah ...
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 07/05/2021 /

RATIONAL est leader mondial sur le marché des appareils de cuisson pour les cuisines professionnelles. Le groupe dispose d’un excellent track record en termes de croissance topline (TMVA CA 2010/2019 : 10.3%), de profitabilité (marge d’EBIT moyenne de 27.7%) et de génération de FCF (103 M€/an). Le manque de visibilité et de catalyseurs à CT ainsi qu’une valorisation exigeante (PE 2023e de 54x vs PE historique de 44x) nous conduisent à initier la couverture avec une recommandation Sous...

Ahmed Ben Salem ...
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/15/2021 /

Since its publication on 25 January 2021, ODDO BHF’s Convictions list has gained 11.3% in absolute terms, i.e. an outperformance of 3.3% vs Stoxx 600. The ongoing cyclical acceleration implies no upheaval to the sector make-up. Conversely, we are making a switch on our IT line with the removal of STMicroelectronics, exposed to Apple, in favour of Infineon for which visibility has improved due to the shortage of semiconductors in the automobile sector. - ...

Ahmed Ben Salem ...
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/04/2021 /

Depuis sa publication le 25 janvier dernier, la liste Convictions ODDO BHF est en hausse de 11,3% en absolu soit une surperformance de 3,3% vs Stoxx 600. L’accélération cyclique en cours n’implique pas de bouleversement dans la composition sectorielle. En revanche nous arbitrons au sein de notre ligne l’IT avec la sortie de STM, exposé à Apple, en faveur d’Infineon dont la visibilité est accrue en raison de la pénurie de semi-conducteurs dans le secteur automobile. - ...

Thanks to a better fundamental star rating, MODERNA sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to MODERNA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date April 13, 2021, the closing price was USD 149.71 and its expected value was estimated at USD 142.02.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch